Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder | 14 | 2020 | 380 | 1.900 |
Why?
|
| Tryptophan | 7 | 2011 | 183 | 1.550 |
Why?
|
| Suicide, Attempted | 4 | 2020 | 373 | 1.220 |
Why?
|
| Serotonin | 7 | 2011 | 323 | 0.970 |
Why?
|
| Antidepressive Agents | 8 | 2020 | 235 | 0.900 |
Why?
|
| Suicidal Ideation | 5 | 2020 | 523 | 0.880 |
Why?
|
| Time Perception | 1 | 2020 | 28 | 0.680 |
Why?
|
| Population Health | 1 | 2021 | 47 | 0.680 |
Why?
|
| Depressive Disorder, Major | 4 | 2010 | 362 | 0.630 |
Why?
|
| Health Equity | 1 | 2021 | 99 | 0.620 |
Why?
|
| Quality Improvement | 3 | 2021 | 1172 | 0.570 |
Why?
|
| Pain | 2 | 2017 | 759 | 0.500 |
Why?
|
| Depression | 3 | 2020 | 1408 | 0.500 |
Why?
|
| Catecholamines | 2 | 2006 | 98 | 0.440 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2004 | 46 | 0.400 |
Why?
|
| Thiophenes | 3 | 2005 | 118 | 0.330 |
Why?
|
| Neurochemistry | 1 | 2010 | 7 | 0.330 |
Why?
|
| Suicide | 1 | 2017 | 645 | 0.320 |
Why?
|
| Norepinephrine | 3 | 2006 | 204 | 0.300 |
Why?
|
| Pain Threshold | 2 | 2019 | 74 | 0.290 |
Why?
|
| Impulsive Behavior | 2 | 2020 | 149 | 0.280 |
Why?
|
| Character | 1 | 2007 | 4 | 0.280 |
Why?
|
| Frontal Lobe | 1 | 2008 | 151 | 0.270 |
Why?
|
| Temperament | 1 | 2007 | 46 | 0.270 |
Why?
|
| Psilocybin | 1 | 2006 | 3 | 0.270 |
Why?
|
| Inflammation | 1 | 2018 | 2836 | 0.260 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2006 | 179 | 0.260 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2006 | 46 | 0.250 |
Why?
|
| Electroencephalography | 1 | 2008 | 433 | 0.240 |
Why?
|
| Mianserin | 2 | 2002 | 5 | 0.240 |
Why?
|
| Middle Aged | 16 | 2020 | 33310 | 0.240 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2005 | 35 | 0.230 |
Why?
|
| Double-Blind Method | 5 | 2010 | 1985 | 0.230 |
Why?
|
| Psychiatric Status Rating Scales | 5 | 2010 | 548 | 0.230 |
Why?
|
| Citalopram | 2 | 2005 | 29 | 0.230 |
Why?
|
| Hallucinogens | 1 | 2006 | 105 | 0.230 |
Why?
|
| Bipolar Disorder | 1 | 2007 | 264 | 0.220 |
Why?
|
| Biogenic Monoamines | 1 | 2004 | 16 | 0.220 |
Why?
|
| Adult | 16 | 2020 | 37724 | 0.210 |
Why?
|
| Brain | 2 | 2006 | 2675 | 0.200 |
Why?
|
| Young Adult | 6 | 2020 | 13163 | 0.190 |
Why?
|
| Humans | 30 | 2023 | 137294 | 0.190 |
Why?
|
| Sexual Behavior | 1 | 2005 | 486 | 0.170 |
Why?
|
| Cross Infection | 1 | 2023 | 247 | 0.170 |
Why?
|
| Analysis of Variance | 3 | 2010 | 1318 | 0.170 |
Why?
|
| Male | 17 | 2020 | 67560 | 0.170 |
Why?
|
| Female | 18 | 2020 | 73052 | 0.170 |
Why?
|
| Interdisciplinary Communication | 1 | 2021 | 192 | 0.160 |
Why?
|
| beta-Endorphin | 1 | 2019 | 8 | 0.160 |
Why?
|
| Neurotensin | 1 | 2019 | 14 | 0.160 |
Why?
|
| Paroxetine | 3 | 2010 | 11 | 0.160 |
Why?
|
| Delivery, Obstetric | 1 | 2020 | 145 | 0.150 |
Why?
|
| Catheter-Related Infections | 1 | 2019 | 90 | 0.150 |
Why?
|
| Social Isolation | 1 | 2019 | 61 | 0.150 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 310 | 0.150 |
Why?
|
| Infection Control | 1 | 2019 | 165 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 1073 | 0.140 |
Why?
|
| Hospitals | 2 | 2020 | 689 | 0.140 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 111 | 0.140 |
Why?
|
| Delay Discounting | 1 | 2018 | 23 | 0.140 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 257 | 0.140 |
Why?
|
| Homovanillic Acid | 2 | 2010 | 10 | 0.130 |
Why?
|
| Methoxyhydroxyphenylglycol | 2 | 2010 | 13 | 0.130 |
Why?
|
| Duloxetine Hydrochloride | 3 | 2005 | 11 | 0.130 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2020 | 252 | 0.130 |
Why?
|
| Buprenorphine | 1 | 2020 | 167 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2002 | 559 | 0.130 |
Why?
|
| Quality of Health Care | 1 | 2021 | 635 | 0.120 |
Why?
|
| Brain Mapping | 1 | 2019 | 505 | 0.120 |
Why?
|
| Chronic Pain | 1 | 2020 | 260 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 434 | 0.120 |
Why?
|
| Anxiety Disorders | 1 | 2018 | 374 | 0.110 |
Why?
|
| Communication | 1 | 2020 | 879 | 0.110 |
Why?
|
| Health Personnel | 1 | 2020 | 704 | 0.110 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2004 | 17 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 994 | 0.090 |
Why?
|
| Risk Factors | 3 | 2019 | 10368 | 0.090 |
Why?
|
| Adolescent | 4 | 2019 | 21499 | 0.090 |
Why?
|
| Comorbidity | 2 | 2007 | 1624 | 0.090 |
Why?
|
| Pain Measurement | 2 | 2019 | 524 | 0.090 |
Why?
|
| Latin America | 2 | 2021 | 95 | 0.080 |
Why?
|
| Neuropeptide Y | 1 | 2010 | 14 | 0.080 |
Why?
|
| Research | 2 | 2011 | 449 | 0.080 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2010 | 26 | 0.080 |
Why?
|
| Electrochemistry | 1 | 2010 | 79 | 0.080 |
Why?
|
| Recurrence | 2 | 2004 | 1059 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 5436 | 0.080 |
Why?
|
| Dominance, Cerebral | 1 | 2008 | 54 | 0.070 |
Why?
|
| Aged | 4 | 2017 | 23851 | 0.070 |
Why?
|
| Venlafaxine Hydrochloride | 2 | 2005 | 14 | 0.070 |
Why?
|
| Cyclohexanols | 2 | 2005 | 13 | 0.070 |
Why?
|
| Psychometrics | 3 | 2007 | 723 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 597 | 0.070 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 562 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2008 | 244 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2006 | 10800 | 0.070 |
Why?
|
| Personality Inventory | 1 | 2007 | 141 | 0.070 |
Why?
|
| Exploratory Behavior | 1 | 2007 | 92 | 0.070 |
Why?
|
| Indoles | 1 | 2010 | 410 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2007 | 313 | 0.060 |
Why?
|
| Intensive Care Units | 2 | 2023 | 802 | 0.060 |
Why?
|
| Affect | 1 | 2008 | 293 | 0.060 |
Why?
|
| Circadian Rhythm | 1 | 2010 | 468 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 2836 | 0.060 |
Why?
|
| Placebos | 1 | 2005 | 199 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 944 | 0.060 |
Why?
|
| Synaptic Transmission | 1 | 2006 | 289 | 0.050 |
Why?
|
| Stereoisomerism | 1 | 2004 | 98 | 0.050 |
Why?
|
| Pandemics | 2 | 2023 | 1623 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 2032 | 0.050 |
Why?
|
| Diabetic Neuropathies | 1 | 2004 | 93 | 0.050 |
Why?
|
| Dopamine | 1 | 2006 | 303 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 1045 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2010 | 3546 | 0.050 |
Why?
|
| Synapses | 1 | 2006 | 427 | 0.050 |
Why?
|
| Neurodegenerative Diseases | 1 | 2004 | 136 | 0.050 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2002 | 65 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2007 | 3283 | 0.050 |
Why?
|
| Caribbean Region | 1 | 2021 | 26 | 0.040 |
Why?
|
| Neuronal Plasticity | 1 | 2004 | 290 | 0.040 |
Why?
|
| Reaction Time | 1 | 2002 | 416 | 0.040 |
Why?
|
| Sex Factors | 1 | 2006 | 2073 | 0.040 |
Why?
|
| Patient Care Bundles | 1 | 2019 | 23 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 2419 | 0.040 |
Why?
|
| Brazil | 1 | 2020 | 167 | 0.040 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 51 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 5125 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2008 | 3439 | 0.040 |
Why?
|
| Gyrus Cinguli | 1 | 2019 | 87 | 0.040 |
Why?
|
| Incidence | 1 | 2005 | 2808 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2002 | 515 | 0.040 |
Why?
|
| Connectome | 1 | 2019 | 85 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2004 | 1788 | 0.030 |
Why?
|
| Focus Groups | 1 | 2020 | 515 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 411 | 0.030 |
Why?
|
| Emotions | 1 | 2002 | 547 | 0.030 |
Why?
|
| Pain Management | 1 | 2020 | 349 | 0.030 |
Why?
|
| Public Health | 1 | 2021 | 579 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2020 | 15639 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2019 | 549 | 0.030 |
Why?
|
| Neurons | 1 | 2004 | 1588 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 786 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2002 | 7607 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 6054 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 6743 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3568 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2006 | 28 | 0.020 |
Why?
|
| Fluvoxamine | 1 | 2005 | 17 | 0.020 |
Why?
|
| Sertraline | 1 | 2005 | 29 | 0.020 |
Why?
|
| Syndrome | 1 | 2006 | 357 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2006 | 219 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 36862 | 0.010 |
Why?
|
| Self-Assessment | 1 | 2003 | 74 | 0.010 |
Why?
|
| Lithium | 1 | 2002 | 43 | 0.010 |
Why?
|
| Cyclopropanes | 1 | 2002 | 90 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2003 | 286 | 0.010 |
Why?
|
| Decision Trees | 1 | 2002 | 94 | 0.010 |
Why?
|
| Morpholines | 1 | 2002 | 121 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 2052 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 406 | 0.010 |
Why?
|
| Congresses as Topic | 1 | 2002 | 234 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 762 | 0.010 |
Why?
|
| Self Efficacy | 1 | 2003 | 395 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 1063 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2002 | 740 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 1577 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2002 | 765 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2003 | 808 | 0.010 |
Why?
|
| Research Design | 1 | 2003 | 1128 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2002 | 1302 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2006 | 7595 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2003 | 5769 | 0.010 |
Why?
|